62208-38-2

Upstream product

• 15964-79-1 methyl (3,4-dimethoxyphenyl)acetate 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 

Downstream Products

• 142231-82-1 N-p-chlorophenyl-4,5-dimethoxy-2-carbomethoxymethylbenzenesulfonamide 
• 1092115-37-1 methyl 2-[2-(phenylaminocarbonylmethyl-sulfamoyl)-4,5-dimethoxyphenyl]acetate 
• 1092115-40-6 methyl 2-[2-(ethoxycarbonylmethyl-sulfamoyl)-4,5-dimethoxyphenyl]acetate 
• 1016637-96-9 2-(2-hydrazinyl-2-oxoethyl)-N,N-dimethyl-4,5-dimethoxybenzenesulfonamide 
• 477887-67-5 methyl 2-(2-(N,N-dimethylsulfamoyl)-4,5-dimethoxyphenyl)acetate 
• 1016637-98-1 2-(N,N-diethylsulfamoyl)-4,5-dimethoxy-phenyl-acetylhydrazide 

Relevant academic research and scientific papers

Anticancer activity of triazolo-thiadiazole derivatives and inhibition of akt1 and akt2 activation

The fusion of 1,2,4-triazole and 1,3,4-thiadiazole rings results in a class of heterocycles compounds with an extensive range of pharmacological properties. A series of 1,2,4-triazolo[3,4-b]-1,2,4-thiadiazoles was synthesized and tested for its enzyme inhibition potential and anticancer activity. The results show that 1,2,4-triazolo[3,4-b]-1,2,4-thiadiazoles display potent anticancer properties in vitro against a panel of cancer cells and in vivo efficacy in HT-29 human colon tumor xenograft in CB17 severe combined immunodeficient (SCID) mice. Preliminary mechanistic studies revealed that KA25 and KA39 exhibit time-and concentration-dependent inhibition of Akt Ser-473 phosphorylation. Molecular modeling experiments indicated that 1,2,4-triazolo[3,4-b]-1,2,4-thiadiazoles bind well to the ATP binding site in Akt1 and Akt2. The low acute toxicity combined with in vitro and in vivo anticancer activity render triazolo[3,4-b]thiadiazoles KA25, KA26, and KA39 promising cancer therapeutic agents.

3,6-disubstituted 1,2,4-triazolo[3,4-b] thiadiazoles with anticancer activity targeting topoisomerase II alpha

Background: Topoisomerase IIα (topIIα) maintains the topology of DNA in order to ensure the proper functioning of numerous DNA processes. Inhibition of topIIα leads to the killing of cancer cells thus constituting such inhibitors as useful tools in cancer therapeutics. Triazolo[3,4-b]thiadiazole derivatives are known for their wide range of pharmacological activities while previous studies have documented their in vitro anticancer activity. The purpose of the current study was to investigate if these chemical compounds can act as topIIα inhibitors in cell-free and cell-based systems. Materials and Methods: The MTT assay was performed in DLD-1, HT-29, and LoVo cancer cells so as to evaluate the antiproliferative activity of KA25, KA26, and KA39 triazolo[3,4-b]thiadiazole derivatives. The KA39 compound was tested as a potential topIIα inhibitor using the plasmid-based topoisomerase II drug screening kit. The inhibitory effect of the three derivatives on topIIα phosphorylation was studied in HT-29 and LoVo cancer cells according to Human Phospho-TOP2A/Topoisomerase II Alpha Cell-Based Phosphorylation ELISA Kit. Moreover, flow cytometry was utilized in order to explore apoptotic induction and cell cycle growth arrest, upon treatment with KA39, in DLD-1 and HT-29 cells, respectively. In silico studies were also carried out for further investigation. Results: All three triazolo[3,4-b]thiadiazole derivatives showed an in vitro antiproliferative effect with the KA39 compound being the most potent one. Our results indicated that KA39 induced both early and late apoptosis as well as cell cycle growth arrest in S phase. In addition, the compound blocked the relaxation of supercoiled DNA while it also inhibited topIIα phosphorylation (upon treatment; P0.001). Conclusion: Among the three triazolo[3,4-b]thiadiazole derivatives, KA39 was shown to be the most potent anticancer agent and catalytic inhibitor of topIIα phosphorylation as well.

NEW 1,2,4-TRIAZOLO-[3,4-b]-1,3,4-THIADIAZOLE DERIVATIVES

Derivatives of 1,2,4-Triazolo-[3,4-b]-1,3,4-thiadiazoles according to formula (I), processes for their production, pharmaceutical compositions containing them and their use in the treatment of cancer.

Formation and ring contraction of benzo[f][1,2]thiazepine-1,1-dioxides from and to benzo[e][1,2]thiazine-1,1-dioxides

Alkoxide-promoted ring expansion of the novel ethyl 2-(6,7-dimethoxy-3-oxo- 3,4-dihydrobenzo[e][1,2]thiazine-1,1-dioxide-2-yl)acetate 3a and analogous 4,4-diethyl derivative 3b and cyclization of methyl 2-[2- (phenylaminocarbonylmethyl sulfamoyl)-4,5-dimethoxyphenyl] acetate 9 to the corresponding new 3-carboxylates and 3-carboxanilide of 7,8-dimethoxy-4-hydroxy- 2,5-dihydrobenzo[f][1,2]thiazepine-1,1-dioxide (5a,b and 10 respectively) is described. Compound 5a was deacylated upon treatment with sodium hydroxide followed by hydrochloric acid to give 7,8-dimethoxy-2,3-dihydrobenzo[f][1,2] thiazepine-1,1-dioxide-4 (5H)-one 8 and its N-ethyl derivative transferred to 6,7-dimethoxy-2-ethyl-3-oxo-3,4-dihydrobenzo[e][1,2]thiazine-1,1-dioxide 7 by the reaction with ethyl methyl ketone in the presence of pyrrolidine. Copyright Taylor & Francis Group, LLC.